Last reviewed · How we verify
Placebo to Reformulated Raltegravir
Placebo to Reformulated Raltegravir is a Integrase strand transfer inhibitor (INSTI) Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for HIV-1 infection in treatment-naive and treatment-experienced patients.
Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.
Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naive and treatment-experienced patients.
At a glance
| Generic name | Placebo to Reformulated Raltegravir |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Raltegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the human genome, thereby halting HIV replication. This reformulated version maintains the same mechanism of action as the original formulation but with potentially improved pharmacokinetic properties.
Approved indications
- HIV-1 infection in treatment-naive and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Insomnia
- Elevated creatine kinase
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Reformulated Raltegravir CI brief — competitive landscape report
- Placebo to Reformulated Raltegravir updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to Reformulated Raltegravir
What is Placebo to Reformulated Raltegravir?
How does Placebo to Reformulated Raltegravir work?
What is Placebo to Reformulated Raltegravir used for?
Who makes Placebo to Reformulated Raltegravir?
What drug class is Placebo to Reformulated Raltegravir in?
What development phase is Placebo to Reformulated Raltegravir in?
What are the side effects of Placebo to Reformulated Raltegravir?
What does Placebo to Reformulated Raltegravir target?
Related
- Drug class: All Integrase strand transfer inhibitor (INSTI) drugs
- Target: All drugs targeting HIV integrase
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-naive and treatment-experienced patients
- Compare: Placebo to Reformulated Raltegravir vs similar drugs
- Pricing: Placebo to Reformulated Raltegravir cost, discount & access